?Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide ? trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer?. - ND

ISTITUTO EUROPEO DI ONCOLOGIA0 个研究点开始时间: 2009年7月24日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Patients with histologically proven primary breast cancer (T2-T3 T4 a-d, N0-3, M0) T2-T4 a-d ER and PgR < 10%, HER2 positive/negative breast cancer Women aged 18?70 years No treatment with previous chemotherapy / endocrine therapy Performance status 0-2 (ECOG scale) No evidence of distant metastatic disease LVEF ≥ 55% at basal echocardiography or MUGA scan
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients with ER and /or PgR ≥ 10% HER2 negative or positive T-2-4 a-d tumors Patients with other non-malignant uncontrolled systemic diseases that would preclude trial entry in the opinion of the investigator. Specifically not eligible are patients with uncontrolled active infection, chronic infection such as active HBV or HCV Patients with distant metastatic disease Patients with a history of any prior ipsilateral or contralateral invasive breast cancer.

发起方